PMID- 19408307
OWN - NLM
STAT- MEDLINE
DCOM- 20090722
LR  - 20211020
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 125
IP  - 3
DP  - 2009 Aug 1
TI  - IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult 
      Glioma Study in the temozolomide era.
PG  - 680-7
LID - 10.1002/ijc.24369 [doi]
AB  - The consistently observed inverse relationship of allergic conditions with glioma 
      risk and our previous demonstration that immunoglobulin E (IgE) levels also were 
      lower in glioma patients than controls suggest that atopic allergy may be related 
      to a mechanism that inhibits or prevents glioma. We sought to extend these 
      results with a new and larger series of patients (n = 535 with questionnaire 
      data; 393 with IgE measures) and controls (n = 532 with questionnaire data; 470 
      with IgE measures). As expected, glioma cases were less likely than controls to 
      report history of allergies [among self-reported cases, Odds ratios (OR) = 0.59, 
      95% confidence interval (CI): 0.41-0.85]. IgE levels also were lower in glioma 
      cases versus controls (OR per unit log IgE = 0.89, 95% CI (0.82-0.98). However, 
      this inverse relationship was only apparent among cases receiving temozolomide, a 
      treatment which became part of the "standard of care" for glioblastoma patients 
      during the study period. Among patients receiving temozolomide, IgE levels in 
      cases whose blood samples were obtained within 30 days of diagnosis were slightly 
      higher than controls, whereas IgE levels in cases whose blood sample was obtained 
      >60 days after diagnosis were significantly lower than controls (OR = 0.80; 95% 
      CI: 0.71-0.89). Thus, although our results robustly confirm the inverse 
      association between allergy and glioma, the results for IgE are affected by 
      temozolomide treatments which may have influenced IgE levels. These results have 
      implications for the study of immunologic factors in glioma as well as for 
      immunotherapy protocols for treating glioma.
FAU - Wiemels, Joseph L
AU  - Wiemels JL
AD  - Department of Neurosurgery and Epidemiology, UCSF, San Francisco, CA 94143-0441, 
      USA.
FAU - Wilson, David
AU  - Wilson D
FAU - Patil, Chirag
AU  - Patil C
FAU - Patoka, Joseph
AU  - Patoka J
FAU - McCoy, Lucie
AU  - McCoy L
FAU - Rice, Terri
AU  - Rice T
FAU - Schwartzbaum, Judith
AU  - Schwartzbaum J
FAU - Heimberger, Amy
AU  - Heimberger A
FAU - Sampson, John H
AU  - Sampson JH
FAU - Chang, Susan
AU  - Chang S
FAU - Prados, Michael
AU  - Prados M
FAU - Wiencke, John K
AU  - Wiencke JK
FAU - Wrensch, Margaret
AU  - Wrensch M
LA  - eng
GR  - R01 CA052689-17/CA/NCI NIH HHS/United States
GR  - ES06717/ES/NIEHS NIH HHS/United States
GR  - P42 ES004705/ES/NIEHS NIH HHS/United States
GR  - R01 CA052689-18/CA/NCI NIH HHS/United States
GR  - CA52689/CA/NCI NIH HHS/United States
GR  - P50 CA097257/CA/NCI NIH HHS/United States
GR  - P50CA097257/CA/NCI NIH HHS/United States
GR  - CA097257/CA/NCI NIH HHS/United States
GR  - R01CA52689/CA/NCI NIH HHS/United States
GR  - R01 CA052689/CA/NCI NIH HHS/United States
GR  - R01 ES006717/ES/NIEHS NIH HHS/United States
GR  - R01 CA089032/CA/NCI NIH HHS/United States
GR  - CA89032/CA/NCI NIH HHS/United States
GR  - ES04705/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use
MH  - Brain Neoplasms/drug therapy/*epidemiology/*immunology/rehabilitation/therapy
MH  - Case-Control Studies
MH  - Confounding Factors, Epidemiologic
MH  - Dacarbazine/*analogs & derivatives/pharmacology/standards/therapeutic use
MH  - Female
MH  - Glioma/drug therapy/*epidemiology/ethnology/*immunology/therapy
MH  - Humans
MH  - Hypersensitivity/blood/*complications
MH  - Immunoglobulin E/*blood
MH  - Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Risk Assessment
MH  - Risk Factors
MH  - San Francisco/epidemiology
MH  - Surveys and Questionnaires
MH  - Temozolomide
PMC - PMC2861569
MID - NIHMS96660
EDAT- 2009/05/02 09:00
MHDA- 2009/07/23 09:00
PMCR- 2010/04/29
CRDT- 2009/05/02 09:00
PHST- 2009/05/02 09:00 [entrez]
PHST- 2009/05/02 09:00 [pubmed]
PHST- 2009/07/23 09:00 [medline]
PHST- 2010/04/29 00:00 [pmc-release]
AID - 10.1002/ijc.24369 [doi]
PST - ppublish
SO  - Int J Cancer. 2009 Aug 1;125(3):680-7. doi: 10.1002/ijc.24369.